Close Menu
Ciente | MarTechCiente | MarTech
    Facebook LinkedIn
    Ciente | MarTechCiente | MarTech
    • Home
    • Marketing Software
      1. Marketing Software
      2. AI
      3. Tech
      4. Development
      5. Software
      6. B2B
      7. View All

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      Assembly Unveils Updated Marketing Mix Modeling App to Enhance Campaign Performance

      May 23, 2025

      Persado Debuts Marketing Compliance Agentic AI For Financial Services

      May 23, 2025

      IRIS Software Group to Invest in Instead, the AI-driven Tax Platform

      May 22, 2025

      Head, World’s First AI Marketer, Sparks Frenzy; Spots Filled Instantly

      May 21, 2025
    • Marketing Automation
      1. Automation
      2. Marketing Automation
      3. CRM
      4. ABM Marketing
      5. Performance Marketing
      6. Influencer Marketing
      7. Event Marketing
      8. Product Marketing
      9. View All

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      Eco-Growth Strategies, Inc. Engages TraDigital Marketing Group to Enhance Investor Relations Services

      May 30, 2025

      HTX DAO and HTX Ventures at Bitcoin 2025: Empowering the Global Rise of the Bitcoin Ecosystem

      May 30, 2025

      How Marketers Adapt to AI Search Shifts: Insights From Info-Tech Research Group

      May 29, 2025
    • Data & Analytics
      1. Marketing Analytics, Performance Tracking & Attribution
      2. Data Analytics
      3. Data
      4. Data Management
      5. Analytics
      6. View All

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Allbound and Channel Mechanics Unite Under a Single Brand: Channelscaler

      May 30, 2025
    • AdTech
      1. Advertising
      2. Adtech
      3. Digital Marketing
      4. Marketing
      5. Technology
      6. Media
      7. Digital
      8. Martech
      9. Social Media
      10. View All

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      Google vs Amazon: Tech Giants Unleash Huge AdTech News to Revolutionize Advertising

      May 28, 2025

      Flat Ads Showcases at MAU Vegas 2025: Advancing Programmatic Advertising Innovations

      May 21, 2025

      Invoca Launches Durable Attribution for Google Ads to Improve Conversions in a Privacy-First World

      May 21, 2025

      DISH Media Unveils AdvantEdge™, A Game-Changer in Unified, Data Driven TV Advertising

      May 12, 2025
    • Strategy & Management
      1. Market Growth
      2. Marketing Strategy
      3. Strategic Partnership
      4. Strategy
      5. Sales
      6. Digital Transformation
      7. Management
      8. Content
      9. View All

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      Faye Partners with Section to Accelerate Workforce AI Readiness

      May 22, 2025

      Peak Toolworks Unveils Redesigned U.S. and Canadian Websites with Enhanced eCommerce Capabilities and Expanded Company Insights

      May 21, 2025

      Infosys and LogicMonitor Collaborate to Transform Business Performance and Reliability of IT Operations

      May 21, 2025

      Nayya Launches on PrismHR Marketplace Through Strategic Partnership

      May 21, 2025
    • CX
      1. customer experience
      2. CX
      3. Customer Engagement
      4. Customer Service
      5. Customer Success
      6. Personalization
      7. View All

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      Socket Fiber Plugs In GOCare Digital Experience Platform to Enhance Customer Engagement

      May 22, 2025

      Fuel Cycle Introduces FC UX, a Modern Replacement for Legacy User Experience Testing Platforms

      May 21, 2025

      PolyAI names The CX 100 for 2025: One hundred visionaries revolutionizing customer experience

      May 8, 2025

      Sitecore Appoints Eric Stine as Chief Executive Officer, Marking Next Phase of Growth and Innovation

      May 1, 2025
    • Ecommerce & Sales
      1. Ecommerce
      2. Partnership
      3. Collaboration
      4. E-commerce
      5. Launch
      6. Transformation
      7. Acquisition
      8. Commerce
      9. Growth
      10. Supply Chain
      11. View All

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      FleishmanHillard Launches Global Executive Advisory to Help Brands Navigate an Uncertain Marketplace

      May 30, 2025

      Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

      May 30, 2025

      ValueLabs Announces Strategic Pivot–Exclusively Offering Outcome-Based Engagements Globally

      May 30, 2025

      Databricks Grows Operations in Costa Rica with New Office Expansion, Deepens Investment in Latin America

      May 30, 2025

      AI Commerce Demands Action: Parcel Perform’s AI Decision Intelligence Redefines E-commerce Delivery Experience

      May 22, 2025

      Quantum Computing Inc. Reports First Quarter 2025 Financial Results

      May 16, 2025

      WEKA Bolsters Executive Leadership Team With New CRO, CPO and CSO Appointments

      April 23, 2025

      Hyland continues the company’s market evolution with the leadership expansion of its global sales organization

      April 14, 2025
    Ciente | MarTechCiente | MarTech
    Home»Data & Analytics»Ionis reports second quarter 2024 financial results
    Data & Analytics

    Ionis reports second quarter 2024 financial results

    By PRNEWSWIREAugust 2, 2024No Comments14 Mins Read
    Facebook Twitter LinkedIn
    Ionis Pharmaceuticals Inc
    Share
    Facebook Twitter LinkedIn

    WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year

    Olezarsen PDUFA December 19, 2024 for FCS

    Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions

    On track to achieve 2024 financial guidance

    CARLSBAD, Calif., Aug. 1, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the second quarter of 2024.

    “Over the first half of this year, we continued to deliver on our goal to bring a steady cadence of medicines to people with serious diseases. The WAINUA launch for hereditary ATTR polyneuropathy (ATTRv-PN) continues to progress well with AstraZeneca. QALSODY is now approved in the EU, expanding the number of patients who can benefit from the first approved treatment for a genetic form of ALS. And we are well positioned for our first independent launch with olezarsen, which was accepted for Priority Review with a December FDA action date for people with familial chylomicronemia syndrome (FCS), a serious and rare disease with no approved treatments in the U.S. Additionally, we completed enrollment in our Phase 3 olezarsen program for the much larger severe hypertriglyceridemia (sHTG) patient population, keeping us on track for data in the second half of next year. And based on recent positive Phase 3 results, we believe donidalorsen, our second planned independent U.S. launch, is positioned to be a preferred choice for people with hereditary angioedema (HAE),” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “We also advanced our next wave of potentially transformational medicines, including announcing plans to independently advance ION582 into a Phase 3 study next year, based on positive data in Angelman syndrome; this program is poised to become the cornerstone of our robust wholly owned neurology pipeline. Our recent achievements, together with multiple upcoming catalysts, position Ionis to deliver next-level value for all stakeholders.”

    Second Quarter 2024 Summary Financial Results(1):

    Three months endedJune 30,Six months endedJune 30,
    2024202320242023
    (amounts in millions)
    Total revenue$225$188$345$319
    Operating expenses$291$279$560$523
    Operating expenses on a non-GAAP basis$260$252$498$469
    Loss from operations($66)($91)($215)($204)
    Loss from operations on a non-GAAP basis($35)($64)($153)($150)
    (1)  Reconciliation of GAAP to non-GAAP basis contained later in this release.

    Financial Highlights

    • Revenue increased for the second quarter and first half of 2024 by 20% and 8% compared to the same periods last year, respectively, primarily driven by an increase in R&D revenue reflecting the value Ionis’ pipeline and technology continues to generate
    • Operating expenses increased in the second quarter and first half of 2024 compared to the same periods last year, reflecting continued strategic investments in late-stage development, including WAINUA for ATTR cardiomyopathy and olezarsen for sHTG, and commercialization efforts for WAINUA, olezarsen and donidalorsen
    • Reaffirmed 2024 financial guidance

    Recent Marketed Medicines Highlights

    • WAINUA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) generated sales of $16 million and $21 million resulting in royalty revenue of $4 million and $5 million in the second quarter and first half of 2024, respectively
    • WAINUA for the treatment of adults with ATTRv-PN approved in Canada
    • SPINRAZA for the treatment of spinal muscular atrophy (SMA) generated global sales of $429 million and $770 million resulting in royalty revenue of $57 million and $95 million in the second quarter and first half of 2024, respectively
    • QALSODY for the treatment of SOD1-ALS granted marketing approval in the EU

    Recent Late-Stage Pipeline Highlights

    • Olezarsen achieved multiple clinical and regulatory milestones that support pursuit of two patient populations with urgent unmet need, familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG):
      • FDA accepted the NDA for patients with FCS for Priority Review with a PDUFA date of December 19, 2024
      • Presented positive Phase 3 Balance study data in patients with FCS with a simultaneous publication in the New England Journal of Medicine
      • Opened Expanded Access Program (EAP) for FCS in the U.S.
      • Completed enrollment for all Phase 3 sHTG studies: CORE pivotal study, CORE2 confirmatory pivotal study and ESSENCE supportive exposure study; on track for data across all three studies in H2:2025
      • Presented positive Phase 2b Bridge study data in patients with HTG and sHTG with a simultaneous publication in the New England Journal of Medicine
    • Donidalorsen achieved multiple clinical milestones positioning it to become the first RNA-targeted prophylactic treatment for people with hereditary angioedema (HAE):
      • Preparing to submit NDA
      • Otsuka preparing to submit MAA; expanded Otsuka EU commercial licensing agreement to include Asia Pacific
      • Presented positive Phase 3 OASIS-HAE study data in patients treated every four weeks or every eight weeks with a simultaneous publication in the New England Journal of Medicine
      • Presented positive Phase 3 OASISplus open-label extension study data in patients treated every four weeks or every eight weeks
      • Presented positive Phase 3 OASISplus switch study data in patients previously treated with other prophylactic therapies
    • Zilganersen (GFAP) Phase 3 study for the treatment of patients with Alexander disease fully enrolled; on track for data in 2025
    • Bepirovirsen Phase 3 studies for the treatment of patients with chronic hepatitis B (CHB) fully enrolled; on track for data in 2026

    Recent Other Pipeline Updates

    • Presented positive Phase 2 data for ION582 (UBE3A), our wholly owned medicine, in patients with Angelman syndrome; preparing for meetings with global regulators ahead of planned Phase 3 study start in H1:2025
    • Presented positive Phase 2 data for ION224 (DGAT2) in patients with metabolic dysfunction-associated steatohepatitis (MASH)
    • Initiated the Phase 1/2 Orbit study of ION356 (PLP1) in patients with Pelizaeus-Merzbacher disease (PMD)
    • Discontinued development of IONIS-FB-LRx for geographic atrophy (GA) and ION541 for amyotrophic lateral sclerosis (ALS) following completion of Phase 2 studies showing favorable safety profiles and good target engagement, but insufficient efficacy to advance into Phase 3 development

    Second Quarter 2024 Financial Results

    “Ionis is at a critical inflection point. We have achieved important development and regulatory milestones for WAINUA, olezarsen and donidalorsen, all of which have significant potential to help patients in need. In parallel, we continue to advance our next wave of potentially transformational medicines,” said Elizabeth L. Hougen, chief financial officer of Ionis. “To drive next-level of value creation for all stakeholders, we remain focused on strategically investing our capital to fully unlock the potential of our promising near-and longer-term portfolio. Our investments are focused on go-to-market preparations for our upcoming planned olezarsen and donidalorsen launches. And with our increased confidence in the potential of WAINUA and olezarsen to address broader patient populations, we are planning additional investments to scale our capabilities in line with the significant potential that these important medicines represent. Additionally, we are investing in our next wave of medicines, including pre-commercialization activities and Phase 3 development for ION582 for Angelman syndrome, which we plan to start in the first half of next year. We expect our investments today and in the years ahead will position Ionis for sustainable growth for years to come.”

    Revenue

    Ionis’ revenue was comprised of the following:

    Three months endedSix months ended
    June 30,June 30,
    2024202320242023
    Revenue:(amounts in millions)
         Commercial revenue:
    SPINRAZA royalties$57$61$95$111
    WAINUA royalties4–5–
    Other commercial revenue:
    TEGSEDI and WAYLIVRA revenue, net8111717
    Licensing and other royalty revenue361518
    Total commercial revenue7278132146
    Research and development revenue:
    Amortization from upfront payments35157729
    Milestone payments53516074
    License fees38203820
    Other services154166
    Collaborative agreement revenue14190191129
    WAINUA joint development revenue12202244
    Total research and development revenue153110213173
    Total revenue$225$188$345$319

    Commercial revenue in the second quarter and first half of 2024 included a new source of royalty revenue with the launch of WAINUA in the U.S. in late January 2024. Ionis’ commercial revenue in the second quarter and first half of 2024 also included royalties from the net sales of QALSODY, which Biogen launched in the U.S. in the second quarter of 2023 and in the EU in the second quarter of 2024.

    R&D revenue in the second quarter and first half of 2024 increased compared to the same periods last year primarily due to the amortization of upfront payments from the new collaborations with Roche and Novartis that Ionis entered into during the second half of last year. In addition, license fees increased year over year as a result of new collaborations Ionis entered into during the second quarter of 2024, including the expanded donidalorsen licensing agreement with Otsuka, which now includes the Asia-Pacific region in addition to Europe. These increases were partially offset by the decrease in WAINUA joint development revenue, which decreased as development activities relating to ATTRv-PN wound down with the launch of WAINUA for this indication.

    Operating Expenses

    Ionis’ operating expenses increased in the second quarter and first half of 2024 compared to the same periods in 2023, consistent with expectations. SG&A expenses increased year over year primarily due to the launch of WAINUA in the U.S. and launch preparation activities for olezarsen and donidalorsen, including establishing the field team for olezarsen. R&D expenses decreased in the second quarter and were essentially flat in the first half of 2024 compared to the same periods last year as several late-stage studies have ended.

    Balance Sheet

    As of June 30, 2024, Ionis’ cash, cash equivalents and short-term investments decreased to $2.1 billion compared to $2.3 billion at December 31, 2023. The Company plans to continue deploying its capital resources toward growth opportunities, and as previously guided, projects to end 2024 with $1.7 billion in cash, cash equivalents and short-term investments. Ionis’ working capital also decreased over the same period primarily due to the Company’s lower cash and short-term investments balance. We expect to make increased strategic investments in the years ahead, with a focus on late-stage programs, wholly owned assets, and our next wave of innovative medicines.

    Webcast

    Management will host a conference call and webcast to discuss Ionis’ second quarter 2024 results at 11:30 a.m. Eastern time on Thursday, August 1, 2024. Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address. To access the Company’s second quarter 2024 earnings slides click here.

    For more information about SPINRAZA and QALSODY, visit https://www.spinraza.com/ and https://www.qalsody.com/, respectively. QALSODY is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).

    INDICATION for WAINUA™ (eplontersen)
    WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

    IMPORTANT SAFETY INFORMATION for WAINUA™ (eplontersen)

    WARNINGS AND PRECAUTIONS
    Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.

    ADVERSE REACTIONS
    Most common adverse reactions (≥9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).

    Please see link to U.S. Full Prescribing Information for WAINUA. 

    About Ionis Pharmaceuticals, Inc.

    For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

    Ionis’ Forward-looking Statement

    This press release includes forward-looking statements regarding Ionis’ business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2023, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

    In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its subsidiaries.

    Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. SPINRAZA® and QALSODY® are registered trademarks of Biogen. WAINUATM is a registered trademark of the AstraZeneca group of companies.

    Ionis Investor Contact:
    D. Wade Walke, Ph.D.
    IR@ionis.com
    760-603-2331

    Ionis Media Contact:
    Hayley Soffer
    media@ionis.com 
    760-603-4679

    IONIS PHARMACEUTICALS, INC.SELECTED FINANCIAL INFORMATIONCondensed Consolidated Statements of Operations(In Millions, Except Per Share Data)
    Three months endedSix months ended
    June 30,June 30,
    2024202320242023
    (unaudited)
    Revenue:
         Commercial revenue:
    SPINRAZA royalties$57$61$95$111
    WAINUA royalties4–5–
    Other commercial revenue11173235
    Total commercial revenue7278132146
    Research and development revenue:
    Collaborative agreement revenue14190191129
    WAINUA joint development revenue12202244
    Total research and development revenue153110213173
    Total revenue225188345319
    Expenses:
          Cost of sales4364
        Research, development and patent222230436428
        Selling, general and administrative654611891
    Total operating expenses291279560523
    Loss from operations(66)(91)(215)(204)
    Other income (expense):
    Interest expense related to the sale of future royalties(18)(18)(36)(33)
    Other income, net18324247
    Loss before income tax expense(66)(77)(209)(190)
    Income tax expense–(8)–(20)
    Net loss($66)($85)($209)($210)
    Basic and diluted net loss per share($0.45)($0.60)($1.43)($1.47)
    Shares used in computing basic and diluted net loss per share146143146143
    IONIS PHARMACEUTICALS, INC.Reconciliation of GAAP to Non-GAAP Basis:
    Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss(In Millions)
    Three months endedJune 30,Six months endedJune 30,
    2024202320242023
    (unaudited)
    As reported research, development and patent
    expenses according to GAAP
    $222$230$436$428
        Excluding compensation expense related to equity awards      (23)(19)(45)(39)
    Non-GAAP research, development and patent
    expenses
    $199$211$391$389
    As reported selling, general and administrative 
    expenses according to GAAP
    $65$46$118$91
        Excluding compensation expense related to equity awards      (8)(7)(17)(14)
    Non-GAAP selling, general and administrative
    expenses
    $57$39$101$77
    As reported operating expenses according to GAAP$291$279$560$523
    Excluding compensation expense related to equity awards      (31)(27)(62)(54)
    Non-GAAP operating expenses$260$252$498$469
    As reported loss from operations according to GAAP($66)($91)($215)($204)
        Excluding compensation expense related to equity awards      (31)(27)(62)(54)
    Non-GAAP loss from operations($35)($64)($153)($150)
    As reported net loss according to GAAP($66)($85)($209)($210)
        Excluding compensation expense related to equity awards
          and related tax effects              
    (31)(27)(62)(54)
    Non-GAAP net loss($35)($58)($147)($156)

    Reconciliation of GAAP to Non-GAAP Basis

    As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis’ non-GAAP results is consistent with how Ionis’ management internally evaluates the performance of its operations.

    IONIS PHARMACEUTICALS, INC.Condensed Consolidated Balance Sheets(In Millions)
    June 30,December 31,
    20242023
    (unaudited)
    Assets:
      Cash, cash equivalents and short-term investments$2,079$2,331
      Contracts receivable2798
      Other current assets223213
      Property, plant and equipment, net7671
      Right-of-use assets167172
      Other assets119105
         Total assets$2,691$2,990
    Liabilities and stockholders’ equity:
      Current portion of deferred contract revenue$94$151
      0.125% convertible senior notes, net – short-term4444
      Other current liabilities168253
      1.75% convertible senior notes, net564562
      0% convertible senior notes, net627625
      Liability related to sale of future royalties, net534514
      Long-term lease liabilities166171
      Long-term obligations, less current portion4142
      Long-term deferred contract revenue189241
      Total stockholders’ equity264387
        Total liabilities and stockholders’ equity$2,691$2,990

    Key 2024 Value Driving Events(1) 

    New Product Launches
    ProgramIndicationAchieved
    WAINUAATTRv-PN• 
    OlezarsenFCS
    QALSODY (EU)SOD1-ALS• 
    Regulatory Actions
    ProgramIndicationRegulatory ActionAchieved
    EplontersenATTRv-PNAdditional OUS filings•  
    EMA approval decision
    Additional OUS approval
    decision(s)
    • 
    OlezarsenFCSNDA filing• 
    FDA approval decision
    EU filing
    Canada filing
    DonidalorsenHAENDA filing
    QALSODYSOD1-ALSEMA approval decision• 
    Key Phase 3 Clinical Data Events
    ProgramIndicationEventAchieved
    OlezarsenFCSBalance study full data •  
    DonidalorsenHAEOASIS-HAE topline data• 
    DonidalorsenHAEOASIS-HAE full data• 
    DonidalorsenHAEOASIS-Plus: OLE + Switch
    data
    • 
    SPINRAZASMADEVOTE study data (high
    dose)
    Key Phase 2 Clinical Data Events
    ProgramIndicationEventAchieved
    DonidalorsenHAE3-year Phase 2 OLE data
    IONIS-FB-LRxIgANPhase 2 data
    IONIS-FB-LRxGAGOLDEN study data—
    ION224 (DGAT2)NASHPhase 2 data • 
    ION582 (UBE3A)Angelman syndromeHALOS study data • 
    ION541 (ATXN2)ALSALSpire study data—
    (1)  Timing expectations based on current assumptions and subject to change.

    SOURCE Ionis Pharmaceuticals, Inc.

    data analytics Marketing technology
    Previous ArticleInsight Assurance Celebrates Major Milestone: $10 Million in ARR
    Next Article Bandwidth Announces Second Quarter 2024 Financial Results
    Leave A Reply Cancel Reply

    Recent Posts

    Unlocking High-Quality Leads: The Strategic Role of Data Mapping and Customer Journeys

    May 7, 2025

    A Modern Marketer’s Guide to OOH Advertising

    April 30, 2025

    5 B2B Lead Magnets That Marketing Teams Need to Invest In

    April 29, 2025
    Stay In Touch
    • Facebook
    • LinkedIn
    Get In Touch
    • Dubai Office:
      IFZA Business Park, DDP, Premises Number 35240-001 Dubai Silicon Oasis Dubai, United Arab Emirates
    • India Office:
      Unit 1001, B wing, Serenity Heights, Andheri East, Mumbai, Maharashtra 400072
    • Phone:+971-557734610
    • Email: hello@ciente.io
    About Us

    Ciente helps MarTech leaders unlock the full potential of data and marketing capabilities. With insights that help CMOs recalibrate marketing efforts, we ensure your tech investment returns value and drives growth, even during economic headwinds.

    Recent Posts

    Unlocking High-Quality Leads: The Strategic Role of Data Mapping and Customer Journeys

    May 7, 2025

    A Modern Marketer’s Guide to OOH Advertising

    April 30, 2025

    5 B2B Lead Magnets That Marketing Teams Need to Invest In

    April 29, 2025

    Sign up for our newsletter

    Get direct access to tech insights, thought leadership, and exclusive research.

      Facebook LinkedIn
      • Privacy & Compliance
      • Subscribe
      • Unsubscribe
      Copyright © 2025 Ciente/ Martech | All Rights Reserved.

      Type above and press Enter to search. Press Esc to cancel.